Does early olaparib administration improve prognosis in patients with HER2-negative metastatic breast cancer and BRCA1 and/or BRCA2 pathogenic variants?: Finding from four cases

Abstract

We herein describe our experience of four patients who had been diagnosed as metastatic breast cancer with BRCA 1/2 pathogenic variants. Prior anthracycline and/or taxane-based therapies needed before administration of PARP inhibitors might be still controversial in terms of patients benefit.